TEM is integrating externally developed AI pathology into its ecosystem to improve risk prediction and personalize prostate ...
The Independent on MSN
New blood test could show if prostate cancer treatment is failing
New blood test could show if prostate cancer treatment is failing - The discovery could lead to personalised treatments for ...
Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...
A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...
Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...
ORLANDO, Fla. (Ivanhoe Newswire) - Prostate cancer is the second leading cause of death in men right behind heart disease. Patients with this cancer often don’t find out until the disease has advanced ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...
Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial-a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results